These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2971817)

  • 1. Correlates of severe or life-threatening toxic effects from trimetrexate.
    Grem JL; Ellenberg SS; King SA; Shoemaker DD
    J Natl Cancer Inst; 1988 Oct; 80(16):1313-8. PubMed ID: 2971817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trimetrexate: predictors of severe or life-threatening toxic effects.
    Eisenhauer EA; Zee BC; Pater JL; Walsh WR
    J Natl Cancer Inst; 1988 Oct; 80(16):1318-22. PubMed ID: 2971818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of trimetrexate in patients with advanced soft-tissue sarcoma.
    Licht JD; Gonin R; Antman KH
    Cancer Chemother Pharmacol; 1991; 28(3):223-5. PubMed ID: 1830249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics.
    Grochow LB; Noe DA; Ettinger DS; Donehower RC
    Cancer Chemother Pharmacol; 1989; 24(5):314-20. PubMed ID: 2758561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric phase I trial and pharmacokinetic study of trimetrexate.
    Balis FM; Patel R; Luks E; Doherty KM; Holcenberg JS; Tan C; Reaman GH; Belasco J; Ettinger LJ; Zimm S
    Cancer Res; 1987 Sep; 47(18):4973-6. PubMed ID: 2957048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics.
    Grochow LB; Noe DA; Dole GB; Rowinsky EK; Ettinger DS; Graham ML; McGuire WP; Donehower RC
    J Natl Cancer Inst; 1989 Jan; 81(2):124-30. PubMed ID: 2909752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypersensitivity reactions to trimetrexate.
    Grem JL; King SA; Costanza ME; Brown TD
    Invest New Drugs; 1990 May; 8(2):211-4. PubMed ID: 2143501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule.
    Stewart JA; McCormack JJ; Tong W; Low JB; Roberts JD; Blow A; Whitfield LR; Haugh LD; Grove WR; Lopez AJ
    Cancer Res; 1988 Sep; 48(17):5029-35. PubMed ID: 2970294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks.
    Fanucchi MP; Walsh TD; Fleisher M; Lokos G; Williams L; Cassidy C; Vidal P; Chou TC; Niedzwiecki D; Young CW
    Cancer Res; 1987 Jun; 47(12):3303-8. PubMed ID: 2953412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I studies of trimetrexate using single and weekly dose schedules.
    Huan SD; Legha SS; Raber MN; Krakoff IH
    Invest New Drugs; 1991 May; 9(2):199-206. PubMed ID: 1831442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.
    Hudes GR; LaCreta F; DeLap RJ; Grillo-Lopez AJ; Catalano R; Comis RL
    Cancer Chemother Pharmacol; 1989; 24(2):117-22. PubMed ID: 2525077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion.
    Bishop JF; Raghavan D; Olver IN; Reece P; Morris R; Friedlander ML
    Cancer Chemother Pharmacol; 1989; 24(4):246-50. PubMed ID: 2526692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections.
    Jolivet J; Landry L; Pinard MF; McCormack JJ; Tong WP; Eisenhauer E
    Cancer Chemother Pharmacol; 1987; 20(2):169-72. PubMed ID: 2959389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
    Schwartz G; Johnson TR; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker JA; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2001 Jul; 7(7):1901-11. PubMed ID: 11448903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of trimetrexate in patients with stage III and IV non-small-cell lung cancer.
    Kris MG; D'Acquisto RW; Gralla RJ; Burke MT; Marks LD; Fanucchi MP; Heelan RT
    Am J Clin Oncol; 1989 Feb; 12(1):24-6. PubMed ID: 2536213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-injection schedule.
    Allegra CJ; Jenkins J; Weiss RB; Balis F; Drake JC; Brooks J; Thomas R; Curt GA
    Invest New Drugs; 1990 May; 8(2):159-66. PubMed ID: 2143500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trimetrexate: clinical development of a nonclassical antifolate.
    O'Dwyer PJ; DeLap RJ; King SA; Grillo-Lopez AJ; Hoth DF; Leyland-Jones B
    NCI Monogr; 1987; (5):105-9. PubMed ID: 2963228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of trimetrexate in malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group study.
    Iscoe NA; Eisenhauer EA; Bodurtha AJ
    Invest New Drugs; 1990 Feb; 8(1):121-3. PubMed ID: 2140563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic study of trimetrexate in combination with cisplatin.
    Hudes GR; LaCreta F; Walczak J; Tinsley P; Litwin S; Comis RL; O'Dwyer PJ
    Cancer Res; 1991 Jun; 51(12):3080-7. PubMed ID: 1828188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation.
    Roberts JD; Poplin EA; Tombes MB; Kyle B; Spicer DV; Grant S; Synold T; Moran R
    Cancer Chemother Pharmacol; 2000; 45(2):103-10. PubMed ID: 10663624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.